Tobira Therapeutics (TBRA) Stock Price, News & Analysis

Company Overview

Tobira Therapeutics, Inc., formerly Regado Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company's lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV. The Company's CVC product candidate is an oral, once-daily immunomodulator that blocks the chemokine receptors, CCR2 and CCR5, which are involved in the inflammatory and fibrogenic pathways in NASH and PSC that cause liver damage, and can lead to cirrhosis, liver cancer or liver failure. It is conducting a global Phase IIb study evaluating CVC in NASH patients with liver fibrosis.

Key Stats

• Today's Range: $42.09 to $42.09
• 50-Day Range: N/A
• 52-Week Range: $3.76 to $42.33
• Volume: N/A
• Average Volume: 251,055 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TBRA Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Tobira Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tobira Therapeutics investors own include AutoZone (AZO), Intuitive Surgical (ISRG), U-Haul (UHAL), Netflix (NFLX), Regeneron Pharmaceuticals (REGN), (GEVA) (GEVA) and Allena Pharmaceuticals (ALNA).

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TBRA
• CIK: 1409690
• Web: www.tobiratherapeutics.com
• Phone: +1-650-7416625
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A